vTv Therapeutics (NASDAQ:VTVT) Releases Earnings Results, Misses Estimates By $0.11 EPS

vTv Therapeutics (NASDAQ:VTVT) posted its quarterly earnings results on Thursday. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11), FiscalAI reports.

vTv Therapeutics Stock Performance

Shares of NASDAQ:VTVT traded up $1.07 during mid-day trading on Thursday, reaching $25.31. 5,098 shares of the company’s stock were exchanged, compared to its average volume of 10,958. vTv Therapeutics has a twelve month low of $12.62 and a twelve month high of $26.99. The firm has a market capitalization of $99.67 million, a price-to-earnings ratio of -8.11 and a beta of 0.66. The business’s fifty day moving average price is $21.22 and its 200-day moving average price is $18.54.

Wall Street Analyst Weigh In

Several brokerages have commented on VTVT. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Tuesday, October 14th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of vTv Therapeutics in a report on Wednesday, August 13th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, vTv Therapeutics presently has a consensus rating of “Hold” and an average price target of $35.50.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.